Vanda Pharmaceuticals

Latest news

• Vanda Pharmaceuticals Announces the Submission of an NDA to the FDA for Bysanti for the Treatments of Acute Bipolar I Disorder and Schizophrenia
  31 March 2025
• FDA Declines to Approve Vanda's Marketing Application for Tradipitant in Gastroparesis
  19 September 2024
• Vanda Pharmaceuticals' Fanapt (iloperidone) Receives U.S. FDA Approval for the Acute Treatment of Bipolar I Disorder
  2 April 2024
• Vanda Pharmaceuticals Announces that U.S. Food and Drug Administration Accepts New Drug Application for Tradipitant for the Treatment of Gastroparesis
  4 December 2023
• Vanda Pharmaceuticals Reports Results from the Phase III Study of Tradipitant in Gastroparesis
  4 February 2022
• FDA Approves Hetlioz (tasimelteon) for the Treatment of Nighttime Sleep Disturbances in Smith-Magenis Syndrome
  1 December 2020
• Vanda Announces Positive Phase II Study Results for Tradipitant in Patients with Gastroparesis
  3 December 2018
• FDA Approves Hetlioz: First Treatment for Non-24 Hour Sleep-Wake Disorder in Blind Individuals
  31 January 2014
• FDA Advisory Committee Recommends Approval of Hetlioz for the Treatment of Non-24-Hour-Disorder (Non-24) in the Totally Blind
  15 November 2013
• Vanda Announces Submission To FDA Of A New Drug Application For Tasimelteon For The Treatment Of Non-24-Hour Disorder In The Totally Blind
  31 May 2013

Drugs Associated with Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc. manufactures, markets and/or distributes more than 2 drugs in the United States. Medications listed here may also be marketed under different names in different countries. Non-US country and region specific information is not available on this page.